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Abstract
Among the many proteases associated with human cancer,
seprase or fibroblast activation protein A, a type II transmem-
brane glycoprotein, has two types of EDTA-resistant protease
activities: dipeptidyl peptidase and a 170-kDa gelatinase
activity. To test if activation of gelatinases associated with
seprase could be involved in malignant tumors, we used a
mammalian expression system to generate a soluble recom-
binant seprase (r-seprase). In the presence of putative EDTA-
sensitive activators, r-seprase was converted into 70- to
50-kDa shortened forms of seprase (s-seprase), which exhib-
ited a 7-fold increase in gelatinase activity, whereas levels
of dipeptidyl peptidase activity remained unchanged. In
malignant human tumors, seprase is expressed predominantly
in tumor cells as shown by in situ hybridization and
immunohistochemistry. Proteins purified from experimental
xenografts and malignant tumors using antibody- or lectin-
affinity columns in the presence of 5 mmol/L EDTA were
assayed for seprase activation in vivo . Seprase expression and
activation occur most prevalently in ovarian carcinoma but
were also detected in four other malignant tumor types,
including adenocarcinoma of the colon and stomach, invasive
ductal carcinoma of the breast, and malignant melanoma.
Together, these data show that, in malignant tumors, seprase
is proteolytically activated to confer its substrate specificity
in collagen proteolysis and tumor invasion. (Cancer Res 2006;
66(20): 9977-85)
Introduction
Seprase was originally identified as a 170-kDa transmembrane
glycoprotein with gelatinolytic activity present at the invadopodia
of human malignant melanoma LOX cells (1, 2). In fact, cloning of
the seprase gene and characterization of its protein showed that
seprase was identical to fibroblast activation protein-a, a protein
proposed to be expressed only on reactive stromal fibroblasts in
common human epithelial cancers (3–7). It has been shown by
immunohistochemistry that seprase is present in tumor cells
and stromal fibroblasts in invasive breast (8–10), gastric (11),
colonic (12, 13), and cervical (14) carcinomas but is absent or
undetectable in all normal tissue cells except in the early stage of
wound healing (15).
Seprase has dual functions in tumor progression. The proteolytic
activity of seprase was shown to promote cell invasiveness toward
the extracellular matrix (1, 2, 15, 16) and support tumor growth and
proliferation (9, 17, 18). Other studies showed that the proteolyt-
ically inactive protein suppressed the transformation of cell lines
and inhibit tumor growth supported by stromal cells (19, 20).
Although different domains of seprase seem to have opposing
effects on tumor progression, the active structure responsible for
tumor invasiveness remains to be elucidated.
Similar to what has been found in dipeptidyl peptidase IV, the
closest homologue to seprase, seprase is capable of cleaving
NH2-terminal prolyl dipeptides from polypeptides and exhibits
dipeptidyl peptidase activity in the presence of 5 mmol/L EDTA
(3–5, 15, 21, 22). Seprase has also been shown to effectively degrade
macromolecule substrates, such as gelatin. Experiments that
affinity labeled the catalytic site with [3H]diisopropyl fluoro-
phosphates (3) and experiments using site-directed mutagenesis,
Ser624 ! Ala624 (5, 17) showed that both dipeptidyl peptidase and
gelatinase activities are EDTA resistant and require a nonclassic
serine protease catalytic center. In addition, the proteolytic activity
of seprase depends on the homodimerization of two 97-kDa
monomers that form a 170-kDa dimer with a centralized catalytic
pocket (3, 23). However, structural and substrate kinetics studies
of the 170-kDa dimeric apoenzyme showed that its catalytic site
was effective in cleaving dipeptides but might be not adequate to
degrade gelatin (23, 24).
To explore the potential function of seprase in the invasion
of tumor cells into the extracellular matrix, we used a novel
mammalian expression system to generate a soluble recombinant
seprase (r-seprase) that lacks seprase cytoplasmic and trans-
membrane domains. This r-seprase is able to dimerize and
exhibits an increase in gelatinase activity compared with
full-length native seprase (n-seprase). In addition, the gelati-
nase activity of r-seprase can be increased further after more
extensive truncation by EDTA-sensitive proteases. EDTA is an
effective inhibitor to the activation of r-seprase gelatinase acti-
vity. We show, for the first time, the expression of seprase in
the tumor cells of ovarian carcinoma by in situ hybridization
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and immunohistochemistry. To look for the presence of shortened
seprase (s-seprase) in vivo , we examined seprase proteins derived
from xenografts and malignant tumors that were purified by
antibody- or lectin-affinity columns in the presence of EDTA. We
found that n-seprase was activated to form 70- to 50-kDa forms
in both xenografts and malignant tumors, suggesting that pro-
teolytic truncation is a biologically relevant mechanism for seprase
activation. In light of the finding that proteolytically activated
seprase is truncated from the NH2 terminus, we discuss a
truncation mechanism for seprase activation, which reduces steric
hindrance and increases accessibility of macromolecular subs-
trates such as gelatin. Because seprase is present at very low levels
in differentiated epithelium and normal tissues but up-regulated
in malignant tumors, it is an attractive therapeutic target for
tumor progression.
Materials and Methods
Plasmid constructs and cells producing r-seprase. Using the pA15
plasmid DNA, which contained seprase cDNA (Genbank accession no.
U76833) as a PCR template (4), the cDNA fragment encoding the
seprase extracellular domain (amino acids 27-760) was amplified with a
forward primer (5¶-AAGGATCCCGCCCTTCAAGAGTTCATAACT-3¶) and a
reverse primer (5¶-AACTCGAGGTCTGACAAAGAGAAACACTG-3¶). The PCR
product, excluding the coding sequences of both the short cytoplasmic
(amino acids 1-6) and hydrophobic transmembrane domains of seprase
(amino acids 7-26), was inserted into a modified pCEP4 vector (Invitrogen,
Carlsbad, CA). This backbone is an EBV-based vector that employs the
cytomegalovirus (CMV) immediate early enhancer/promoter for high-level
transcription of recombinant genes and carries an EBV replication origin
(oriP) to permit its extrachromosomal replication in human cells. Compared
with pCEP4, the modified vector additionally contains the coding sequences
of a secretion signal from the V-J2-C region of the mouse Ign chain and a
V5-His fusion tag, derived from pSecTag/FRT/V5-His-TOPO vector (Invi-
trogen). The cDNA sequence of the seprase extracellular domain was
inserted, in frame, along with the NH2-terminal secretion signal and the
COOH-terminal V5-His tag, allowing efficient secretion, easy detection
(by anti-V5 antibody; Invitrogen), and rapid purification (by HisBind
Resin columns; Novagen, Madison, WI) of recombinant seprase. The final
construct was verified by sequencing both DNA strands and named pE15.
293-EBNA monkey kidney cells (Invitrogen) that were intended for use
with vectors containing an EBV origin of replication (oriP) were maintained
in complete medium [DMEM (Life Technologies, Gaithersburg, MD), 10%
fetal bovine serum (Life Technologies), 2 mmol/L L-glutamine, 100 units/mL
penicillin, and 100 mg/mL streptomycin] supplemented with 250 Ag/mL
G418. Plasmid pE15 was transfected into 293-EBNA cells using Lipofect-
AMINE reagent (Life Technologies) according to the manufacturer’s
instruction. After transfection, cells were initially cultured in complete
medium supplemented with 250 Ag/mL G418 and 200 Ag/mL Hygromycin B
(Life Technologies), then cultured in protein-free HyQ PF-293 medium
(HyClone, Logan, UT) containing 250 Ag/mL G418 and 200 Ag/mL
Hygromycin B. Cell viability was checked with a trypan blue (Life
Technologies) exclusion test. Freshly collected culture medium was filtered
with four layers of filter paper (Whatman) at room temperature and
loaded into an equilibrated DEAE Sepharose Fast Flow column (Sigma,
St. Louis, MO) at 4jC. R-seprase was eluted with a NaCl gradient from
0 to 1.0 mol/L in 10 mmol/L phosphate buffer (pH 7) and then absorbed
by a wheat germ agglutinin (WGA)-affinity chromatography column
(Amersham Pharmacia Biotech, Piscataway, NJ). After being eluted with
0.5 mol/L N-acetylglucosamine (Sigma) in PBS, r-seprase was further
purified by the charged HisBind Resin column (Novagen). The following
elution was done either with the elution buffer containing 1 mol/L
imidazole or with the stripping buffer containing 0.1 mol/L EDTA. Eluted
protein was concentrated to 400 AL with an ULTRAFREE-15 Centrifugal
Filter Device (Millipore, Bedford, MA) and fractionated with a Superdex
200 Prep grade gel filtration column (Amersham Pharmacia Biotech).
R-seprase was tracked throughout the procedure by the soluble dipeptidyl
peptidase assay (15).
In vitro invasion assay. For the evaluation of cell invasiveness,
glutaraldehyde-cross-linked gelatin films were prepared with a small
modification of the method described previously (25). Briefly, 16-well
Lab-Tek Chamber Slides (Nalgene Nunc International, Naperville, IL)
were coated with a layer of 5% gelatin (Sigma) and 2.5% sucrose in PBS,
air-dried, and then fixed with 0.5% glutaraldehyde in PBS on ice for
10 minutes. FITC-labeled human fibronectin (Becton Dickinson Labware,
Mountain View, CA; 50 Ag/mL) was coupled on the surface of the cross-
linked gelatin film. Cells (1,000 per well) were seeded on the films and
cultured for 2 days in the complete medium. After being fixed by 4%
formaldehyde and permeabilized by 0.1% Triton X-100, the cells were
stained by Phalloidin-CPITC (Sigma; 50 Ag/mL in PBS). Cells were
photographed with a Plan Fluor ELWD 40/0.60 objective on an ECLIPSE
TE300 microscope (Nikon, Tokyo, Japan) coupled to a SONY Digital Camera
DKC-5000 where the FITC and CPITC labels were photographed using
epifluorescence microscopy.
Monoclonal antibodies recognizing seprase. Rat monoclonal anti-
bodies (mAb) D8, D28, and D43 are directed against human placental
n-seprase (3, 4). Rat mAb E97 was developed using heat-denatured human
placental seprase as an immunogen and screened by Western immuno-
blotting. Rat mAb E97 is particularly useful in identifying both monomeric
and dimeric forms of denatured seprase on immunoblots, but it does not
recognize nondenatured seprase dimers in ELISA or soluble enzymatic
assays (see Fig. 1D).
To generate mouse mAbs directed against r-seprase, BALB/c inbred
mice (Taconic, Hudson, NY) were immunized using 10 Ag of purified
r-seprase. Splenocytes and Sp2/0-Ag14 cells (American Type Culture
Collection, Rockville, MD) were fused. Hybridomas were screened by ELISA.
Briefly, Microtiter U-bottomed polyvinyl chloride 96-well plates (Dynex
Technologies, Chantilly, VA) were coated with r-seprase and blocked with
5% bovine serum albumin in PBS. Coated r-seprase was subjected to
sequential incubations with Hybridoma supernatant and anti-mouse IgG
peroxidase-conjugates (Sigma). The bound secondary antibody was
detected with 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammo-
nium salt solution (Sigma), and absorbance at 410 nm was detected with a
Microplate Spectrophotometer System equipped with SOFTmax Pro version
1.3.1 (Molecular Devices, Sunnyvale, CA). Hybridomas secreting mAbs
against r-seprase were confirmed by soluble enzymatic assays and Western
immunoblotting analyses. The isotype of each mAb was determined by
ImmunoType Mouse Monoclonal Antibody Isotyping kit (Sigma). Each of
mAb 65, mAb 68, mAb 82, and mAb 90 was created as described above;
all were characterized as immunoglobulin isotype IgG1. Hybridoma cells
were cultured in Cellgro Protein Free Medium (Mediatech, Herndon, VA)
to prepare mAbs for isolation with a Protein G Sepharose 4 column
(Amersham Pharmacia Biotech) and a Superdex 200 Prep Grade Gel
Filtration column.
Studies on human tumor tissues. The human subject protection
protocol for collection of tumor tissues from patients with malignant
diseases has been reviewed and approved by the institutional review board
at Stony Brook University. Malignant tumors and adjacent normal tissues
were also obtained from National Disease Research Interchange (Phila-
delphia). Sample preparations and methods involving antibody staining of
formalin-fixed, paraffin-embedded tissue samples for immunohistochemis-
try as well as the parallel analysis of gelatinolytic activities and proteins
specific for seprase by gelatin zymography and Western immunoblotting
were done as described previously (11, 12). Seprase was isolated from tumor
lysates using WGA lectin-affinity or immunoaffinity purification procedures
as described (15). Soluble enzymatic assays determining dipeptidyl
peptidase and gelatinase activities of purified protein were done as
described (15).
In situ hybridization. In situ hybridization was done to reveal seprase
mRNA expression in tumor tissue sections. Briefly, a DNA template for
transcription of an antisense RNA probe was amplified with PCR using
seprase cDNA as template. The primers (5¶-GATTCTTCCTCCTCAATTTG-3¶
and 5¶-TAATACGACTCACTATAGGGTCACCTTGGAAAGCTGTTC-3¶) were
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designed so that the resulting PCR product of 190 bp had no significant
homology to other genes, and that a T7 bacteriophage promoter was added
to one end. Similarly, a DNA template for control sense RNA probe was
amplified by using two primers (5¶-TAATACGACTCACTATAGGGATTC-
TTCCTCCTCAATTTG-3¶ and 5¶-GTCACCTTGGAAAGCTGTTC-3¶) that
added the T7 promoter to the other end of the PCR product. Specific
FITC-labeled antisense and sense RNA probes were synthesized by in vitro
transcription. Template DNA was removed by digestion with RNase-free
DNase I. RNA probes were hybridized to sections of formalin-fixed, paraffin-
embedded tumor tissues that were obtained as described above for
immunohistochemistry. The FITC-labeled probes were revealed with anti-
FITC mouse antibodies, anti-mouse antibodies, and APAAP (a mixture of
alkaline phosphatase and mouse anti-alkaline phosphatase antibodies)
followed by colorimetric substrates nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate. Finally, the tissue sections were counterstained
with Nuclear Fast Red, dehydrated, and mounted.
Results and Discussion
Isolation of r-seprase. We used a novel approach to express
seprase with an active gelatinase activity, in which the cytoplasmic
and transmembrane domains were deleted, a secretion signal
was added, and a novel mammalian expression system was used
(Fig. 1A). Specifically, the seprase cDNA sequence that encodes
the entire extracellular domain of 734 amino acids was cloned
downstream of a CMV promoter and inserted between an NH2-
terminal secretion signal and a COOH-terminal V5-His tag in a
modified pCEP4 vector (Fig. 1A). Seprase cDNA sequences,
encoding the predicted cytoplasmic domain and transmembrane
domain, were excluded. The newly constructed r-seprase expres-
sion vector was named pE15. 293-EBNA cells were transfected
with pE15 and cultured in the HyQ PF-293 protein-free medium.
R-seprase was affinity purified and subjected to Western immuno-
blotting and proteolysis assays.
To identify 170-kDa n-seprase dimers and 97-kDa monomeric
subunits, gelatin zymography incubated in conditions containing
5 mmol/L EDTA and Western immunoblots using antibodies
directed against seprase subunits can be used (3, 4). Similarly,
r-seprase was found to be a 160-kDa dimer with gelatinase activity
that can be dissociated into two proteolytically inactive 90-kDa
Figure 1. Isolation and characterization of r-seprase. A, r-seprase expression vector pE15. The cDNA regions that encode predicted domains of seprase are indicated:
C, cytoplasmic domain, amino acids 1 to 6; TM, transmembrane domain, amino acids 7 to 26; S, stalk region, amino acids 27 to 48; GR, glycosylation-rich
region, amino acids 49 to 314; CR, cysteine-rich domain, amino acids 305 to 466; CAT, catalytic domain, amino acids 500 to 760. The cDNA fragment that encodes
r-seprase lacks the cytoplasmic and transmembrane domains and was inserted into a CMV promoter-driven expression cassette containing an NH2-terminal mouse
Ign secretion signal and a COOH-terminal V5-His tag. B, a gelatin zymogram (left ) and a corresponding Western immunoblot (right ) of r-seprase. The culture medium
conditioned by the pE15 transfected 293-EBNA cells was prepared under non-boiled () or boiled (+) conditions and subsequently resolved on a gelatin zymogram
and a Western immunoblot using anti-V5 antibody. The purified protein, when boiled for 3 minutes, completely dissociates into 90-kDa inactive monomers, whereas
the proteins remain mostly in dimeric form if not subjected to boiling. The serine gelatinase activity of r-seprase was detected by incubating the zymogram in the
presence of 5 mmol/L EDTA to quench metalloprotease activity. Note that both r-seprase dimers and monomers were present in the medium conditioned by
transfectants; however, the monomers were gelatinolytically inactive. C, dissociation of the active 160-kDa r-seprase into the inactive 90-kDa monomer detected by
gelatin zymography. Freshly purified r-seprase is active at 160 kDa (Fresh). Moderate activity is detected in the dimerized portion of r-seprase samples stored at 20jC
because a portion has dissociated into 90-kDa inactive monomers (Stored ). Samples stored at 20jC and then subsequently incubated at 37jC overnight in the
presence of 5 mmol/L EDTA also have moderate activity in the portion that remained dimeric; however, a large portion dissociated into 90-kDa inactive monomers
(Incubated ). Note that r-seprase dimers create white bands against the dark gray background due to their gelatinase activity, whereas the monomers have no gelatinase
activity and therefore appear as black bands compared to the gelatin background. D, the proteolytic activities of r-seprase. The seprase-specific dipeptidyl
peptidase and gelatinase activities were measured using immunocaptured protein in the soluble enzymatic assays under nondenaturing conditions containing 5 mmol/L
EDTA as described (15). Seprase was captured from culture medium conditioned with pE15-transfected 293-EBNA cells using rat mAbs D8 and D43 (against
n-seprase), mAb E97 (against denatured seprase monomeric subunits and their shortened forms), and mouse mAbs 90 and 65 (against r-seprase dimer). The dipeptidyl
peptidase (Gly-Pro-pNA cleavage) and gelatinase (DQ gelatin degradation) activities of the isolated r-seprase were measured in parallel. * (above the columns),
P < 0.05, significant increase in activity compared with the PBS control. E, specificity of gelatinase activity of n-seprase and r-seprase revealed by parallel gelatin
zymography and Western immunoblotting analyses; 10 and 1 AL of LOX cell Triton X-100 detergent lysate (n-sep) and the concentrated culture medium conditioned by
the pE15 transfected 293-EBNA cells (r-sep) were loaded into parallel SDS gels. One was subjected to gelatin zymography in 5 mmol/L EDTA conditions (left) for
serine-type gelatinase detection and the other by Western immunoblotting using mAb 90 (right ) for assessment of n-seprase and r-seprase protein. F, mixing of the
r-seprase with different amounts of the detergent extract containing n-seprase to test for the presence of endogenous seprase inhibitors. From 1 to 10 AL of LOX
cell Triton X-100 detergent lysate (n-sep ) were mixed with 10 AL of the concentrated culture medium conditioned by the pE15-transfected 293-EBNA cells (r-sep ).
Mixtures were subjected to gelatin zymography in 5 mmol/L EDTA conditions for assessment of possible inhibition of gelatinase activity specific for r-seprase.
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subunits (Fig. 1B-C). Parallel SDS PAGE gelatin zymography
and Western immunoblotting showed that the 160-kDa dimer
degraded gelatin, but the 90-kDa monomer could not (Fig. 1B-C).
In addition, the 160-kDa dimers captured by mAbs D8, D43, 90,
or 65 exhibited dipeptidyl peptidase and gelatinase activities, but
the dissociated subunits isolated by mAb E97 did not (Fig. 1D).
In contrast to the previously proposed role of the transmembrane
domain holding subunits together (3, 4), the present data show that
the cytoplasmic and transmembrane domains of seprase are not
required for its subunit dimerization nor for its enzymatic
activities.
Proteolytic truncation of seprase activates its gelatinase
activity but not its dipeptidyl peptidase activity. We have
obtained several lines of evidence to suggest that NH2-terminal
truncation of seprase activates its gelatinase activity but does
not affect its dipeptidyl peptidase activity. Initially, we compared
the gelatinase activity of n-seprase with that of r-seprase. Because
the dimeric forms of both n-seprase and r-seprase were recog-
nized by mAb 90 (Fig. 1E), mAb 90 was used in Western immu-
noblotting to quantify relative amounts of the r-seprase and
n-seprase protein. When similar amounts of soluble r-seprase
and membrane-bound n-seprase protein were loaded on gelatin
zymograms to compare the gelatinase activity, the gelatinase
activity of r-seprase dimer is considerably higher than that of
the n-seprase dimer (Fig. 1E). Alternatively, the low gelatinase
activity in the membrane bound n-seprase could be due to the
presence of endogenous inhibitors. To test this, different amounts
of the detergent extract containing n-seprase were mixed with a
given amount of r-seprase, and the mixtures were subjected to
gelatin zymography in 5 mmol/L EDTA conditions (Fig. 1F). The
gelatinase activity specific for r-seprase remained at similar
levels, suggesting the absence of endogenous seprase inhibitors
Figure 2. Purification and proteolytic activities of r-seprase. A, SDS-PAGE analysis on purified r-seprase. The r-seprase samples indicated were increasingly and
sequentially purified by the DEAE Sepharose column (DEAE ), the WGA-affinity chromatography column (WGA ), and the HisBind Resin column (His ) from the
culture medium conditioned by pE15-transfected 293-EBNA cells. The samples were then heated to 100jC for 3 minutes in SDS sampling buffer and separated by
SDS-PAGE. The gel was stained with Coomassie brilliant blue. Each lane corresponds to the dissociated monomers of r-seprase present in 10 mL of original culture
medium. B, increased gelatinase activity of purified r-seprase incubated at 37jC. R-seprase samples were purified as above, but not heated, were incubated
at 4jC (left) or 37jC (right ) overnight and then subjected to gelatin zymography in 5 mmol/L EDTA conditions. The top two arrows show the 100- to 85-kDa gelatinases,
and the lower two arrows indicate the 70- to 50-kDa gelatinases that were present only in the less purified fractions, which were potentially exposed to other
proteases. Each lane corresponds to the r-seprase present in 10 mL of original culture medium. C, activation of the 160-kDa r-seprase into 100- to 85-kDa and 70- to
50-kDa gelatinases (arrows ) by EDTA-sensitive protease. R-seprase was enriched by WGA-affinity chromatography column and incubated at 4jC or 37jC for
1 day in the presence or absence of 5 mmol/L EDTA (indicated by 4jC, 37jC + EDTA, and 37jC  EDTA, respectively) and then subjected to gelatin zymography
in 5 mmol/L EDTA conditions and Western immunoblotting using mAb E97 (against seprase subunits and shortened forms that were denatured by Western
immunoblotting transfer buffer). The top two arrows show the 100- to 85-kDa gelatinases, and the lowest arrow indicates the 50-kDa gelatinases. D, activation of
r-seprase increases gelatinase activity but not DP activity. R-seprase was enriched by a WGA-affinity chromatography column and incubated at 4jC or 37jC for 1 day
in the presence or absence of 5 mmol/L EDTA (indicated by 4jC, 37jC + EDTA, and 37jC  EDTA, respectively) and then subjected to the soluble enzymatic assays
as described (15). PBS was used as a negative control in the soluble enzymatic assay. Columns, mean; bars, SD. * (above the column), P < 0.001, a significant
increase in gelatinase activity of truncated seprase.
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associated with the membrane extract. Together, these data show
that the greater gelatinase activity of r-seprase is a result of
truncation of the native form.
Previous investigations that used detergents to extract the
membrane bound n-seprase showed a specific gelatinase activity of
n-seprase at 170 kDa (1, 3, 7). However, the use of detergents for
n-seprase extraction might confer the detected gelatinase activity
by opening the protein to increase the availability of its catalytic
site for macromolecular substrates, whereas n-seprase in its
cellular environment in vivo may not exhibit any activity until it
is proteolytically activated.
Proteolytic truncation of r-seprase resulted in further increase
in gelatinase activity (Fig. 2). The gelatinase activation occurs
readily in r-seprase purified by DEAE Sepharose and WGA-
affinity chromatography columns that contain >10% of impurity
(Fig. 2A-B) but is not noticeable in samples of r-seprase purified
by HisBind Resin column that are >95% pure (Fig. 2A-B).
Proteolytically activated seprase forms have molecular masses
of 100 to 85 kDa and 70 to 50 kDa on gelatin zymograms (Fig. 2B)
that can be recognized by mAb E97 on a parallel Western
immunoblot (Fig. 2C). The smaller, activated gelatinases reduce in
fraction with increasing purification (DEAE > WGA > His), sug-
gesting the involvement of other proteases necessary for seprase
activation.
The involved protease for r-seprase activation is an EDTA-
sensitive endogenous enzymatic activator (Fig. 2C). When the
r-seprase samples, partially purified by DEAE Sepharose and
WGA-affinity chromatography columns, were incubated at 4jC
or 37jC for 1 day in the presence or absence of 5 mmol/L EDTA
(Fig. 2C) and then subjected to gelatin zymography developed in
the presence of 5 mmol/L EDTA and Western immunoblotting
using mAb E97, the activated seprase forms only appeared in the
r-seprase sample that was incubated at 37jC in the absence of
EDTA (Fig. 2C). Similarly, when these same r-seprase samples were
subjected to soluble enzymatic assays for dipeptidyl peptidase
and gelatinase activities specific for seprase, the r-seprase sample
incubated at 37jC in the absence of EDTA exhibited a 7-fold increase
in gelatinase activity but did not increase its dipeptidyl peptidase
activity (Fig. 2D). Incubation of r-seprase at 4jC or 37jC in
the presence of EDTA did not significantly change the dipeptidyl
peptidase and gelatinase activities of r-seprase (Fig. 2D). Note
that both gelatin zymography and soluble enzymatic assays for
dipeptidyl peptidase and gelatinase activities specific for seprase
Figure 3. Expression and activity of n-seprase in LOX melanoma cell lines
and tumor tissues from a xenograft model. A, n-seprase in LOX cell lines: sephigh
and seplow. LOX cells transfected with the control pGUS vector express high
levels of seprase, whereas transfection with the pGUS-SEP 1384 vector utilized
RNA interference (RNAi ) creates a cell line with limited seprase expression.
Cell lysates of the two LOX cell lines (sephigh and seplow) were subjected to
SDS-PAGE followed by Western immunoblotting under non-boiling (for mAb 90)
and boiling conditions (for mAb E97 and mAb anti-actin). The lane labeled
r-sep is the positive control r-seprase; the band labeled anti-actin serves
as a protein loading control. B, n-seprase in experimental tumors created
from the two LOX cell lines: sephigh and seplow. Tumors were lysed with
EDTA-containing buffer. N-seprase was isolated from tumor tissue lysates
by immunoprecipitation using mAb D8-D28-D43 conjugated beads that
specifically target seprase antigen. The beads-antigen complexes were boiled
in SDS-PAGE loading buffer to release seprase polypeptides, and separated
via SDS-PAGE. Subsequent Western immunoblotting using rat mAb E97
revealed bands corresponding to n-seprase polypeptides of 97, 65, 35, and
25 kDa (arrows ). Antibody IgG fragments released from the beads, including
linked heavy and light chains (.n), heavy chain alone (.), and light chain alone
(n), were also detected. R-seprase (r-sep ) was used as a positive control.
The negative control (control) was a protein sample derived from the antibody
beads that were not mixed with tumor lysates. C, seprase specific dipeptidyl
peptidase and gelatinase activity in experimental tumors created from the two
LOX cell lines: sephigh and seplow. Tumor tissue lysates were applied to plates
coated with mAb D8 to specifically capture active seprase forms. The soluble
enzymatic assays were conducted in the presence of 5 mmol/L EDTA to inhibit
any metalloprotease activity. The experiment was done in triplicate. Columns,
mean; bars, SD. * (above the column), P < 0.001, a significant increase in
seprase activity compared with the seprase knockdown tumors. D, degradation/
invasion of fibronectin-coated cross-linked gelatin substrata comparing two
conditions of LOX cells: LOX (sephigh) and LOX (seplow). LOX cells transfected
with pGUS and pGUS-sep1384, respectively, were cultured on FITC-fibronectin-
coated cross-linked gelatin films. After fixation and Phalloidin-CPITC staining,
cells were visualized by epifluorescence microscopy of CPITC to visualize cell
location, and the same fields were then photographed by epifluorescence
microscopy of FITC to visualize the sites of matrix degradation left behind
the migrating cells, which are shown by dark spots on the green background.
Bar, 50 Am.
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were developed in the presence of 5 mmol/L EDTA to suppress
metalloprotease activity.
Overall, the gelatinase activity of the activated r-seprase was
elevated as shown by gelatin zymography (Fig. 2B-C) and soluble
dipeptidyl peptidase and gelatinase assays (Fig. 2D). However,
the dipeptidyl peptidase activity of different forms of r-seprase
was not increased by proteolytic truncation (Fig. 2D). These data
show that proteolytic truncation of seprase reduces steric
hindrance for the gelatin substrate but not the dipeptidyl peptidase
substrate and increases the gelatinolytic activity of seprase.
Truncation is likely to occur at the NH2-terminal region because
the catalytic center of seprase is localized to the distal end of
COOH terminus, and because catalytic activity is retained in these
shortened forms.
Interestingly, the anti-V5 antibody and the HisBind Resin
column were not able to capture the truncated 50-kDa form (data
not shown). Because the anti-V5 antibody and HisBind Resin
column are able to bind to the full-length r-seprase dimer and
monomer, it is possible that the 50-kDa form might have lost its
COOH-terminal V5 and His tags during proteolytic cleavage and
production of the shorter forms. The cleavage site of the COOH-
terminal truncation is not known. It is likely to be within the
26-amino-acid residues after His734 of the catalytic triad, as the
truncated 50-kDa form remains active.
Expression and activity of n-seprase. We established LOX
melanoma cells with contrasting levels of seprase expression:
sephigh and seplow. LOX cells with low seprase expression (seplow)
were generated by RNA interference knockdown using the vector
pGUS-SEP1384 followed by stable cell selection, and cells with high
seprase (sephigh) were similarly transfected with a control pGUS
vector. The sephigh cells produced high levels of n-seprase (Fig. 3A)
and invaded fibronectin-coated gelatin films in vitro (Fig. 3D),
whereas the seplow cells did not. Seprase is only prominent in the
cell lysate derived from sephigh cells, in which the dimers and intact
97-kDa subunits of n-seprase could be shown by Western immu-
noblotting (Fig. 3A).
We also established experimental human tumors from sephigh
and seplow cells and determined the subunit composition of
s-seprase in the human tumors developed in immunodeficient
mice (Fig. 3B). We found that tumors derived from sephigh cells
produced seprase peptides of 97, 65, 35, and 25 kDa, but those
from seplow cells did not (Fig. 3B); consistently, the former also
exhibited higher dipeptidyl peptidase and gelatinase activities
specific for seprase than the latter (Fig. 3C).
Detection of s-seprase in human tumors.We detected seprase
mRNA expression in tumor tissues using in situ hybridization.
In Fig. 4A to B , an example of ovarian adenocarcinomas shows
that seprase mRNA is mainly localized to tumor cells (Fig. 4A, open
arrows) and is less prominent in stromal cells (Fig. 4A, arrows),
suggesting that the majority of seprase is produced by tumor cells.
Activated seprase may attach to stromal matrices during its
proteolytic degradation of the substrates.
Immunohistochemical techniques were used to evaluate the
expression of seprase protein in surgically removed tumors using
a panel of mAbs (D8, D28, and D43) that recognized seprase
as described (11–14). In Fig. 4C to D , an example of ovarian
carcinoma reveals positive immunostaining at tumor cells,
indicated by their brown membrane/cytoplasm, against cellular
nuclei counterstained by hematoxylin in blue. This is compared
with the control antibody staining that only shows a blue
hematoxylin stain (Fig. 4D).
Affinity purification of seprase protein from ovarian adenocarci-
nomas revealed seprase activation in malignant ovarian tumors
with shortened seprase forms (s-seprase) composed of 65-, 35-, and
25-kDa polypeptides (Fig. 4E). The tumors with seprase activation
exhibited high dipeptidyl peptidase and gelatinase activities
specific for seprase (Fig. 4F).
Similar findings were made in other types of malignant
tumors. In Fig. 5A to B , an example of malignant melanoma
shows positive immunostaining for seprase, indicated by a pink
or red cytoplasmic stain, against cellular nuclei counterstained
by hematoxylin in blue, compared with the control that only
shows the blue hematoxylin stain. To confirm that the s-seprase
forms found in the tumor tissues were actively degrading
gelatin, WGA-binding proteins purified from paired tumor and
adjacent tissues from the same patients were analyzed in parallel
by gelatin zymography and immunoblotting using both mAbs
D8 (directed mainly against seprase 170-kDa dimeric form and
97-kDa dissociated monomeric form) and E97 (against all seprase
Figure 4. Expression and activity of n-seprase in human ovarian carcinoma.
A and B, n-seprase mRNA expression in human ovarian carcinoma tissues.
In situ hybridization was performed on formalin-fixed, paraffin-embedded tumor
sections using FITC-labeled antisense (A ) or sense (B) RNA probes for seprase.
FITC-labeling was revealed using the alkaline phosphatase colorimetric
substrates 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium, which
show a purple/blue staining. Counterstaining using nuclear fast red appears red.
Seprase mRNA is mainly localized in tumor cells (open arrows ) and is less
prominent in stromal cells (arrows ). Bar, 100 Am. C and D, n-seprase protein
expression in human ovarian carcinoma tissues. Immunohistochemistry was
carried out on formalin-fixed, paraffin-embedded tumor sections using mAb D8
against seprase (C ) or a control rat antibody (D ). The positive staining is brown,
whereas the counterstaining using hematoxylin appears blue. Seprase protein
was mainly detected in tumor cells (open arrows ) instead of stromal cells
(arrows ). Bar, 100 Am. E, isolation of n-seprase truncated forms from human
ovarian carcinoma tissues. Tumor tissues were lysed in the presence of
5 mmol/L EDTA. N-seprase in tumor lysates (OC 267 and OC244) was isolated
and identified as described in Fig. 3B . Note that the top two arrows indicate
dissociated seprase polypeptides at 97 and 65 kDa; the lower two arrows show
dissociated seprase polypeptides at 35 and 25 kDa. F, seprase-specific
dipeptidyl peptidase and gelatinase activity in human ovarian carcinoma tissues.
Tumor tissue lysates were applied to plates coated with mAb D8 to specifically
capture active seprase forms. The soluble enzymatic assays were conducted
in the presence of 5 mmol/L EDTA to inhibit any metalloprotease activity.
*, P < 0.001, compared with the PBS-negative control.
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forms including active s-seprase forms, in Western immunoblots,
in which seprase forms were partially denatured by protein transfer
buffer) as described (11, 12). Figure 5C to F illustrates examples
of carcinomas of the colon (Fig. 5C), stomach (Fig. 5D) and breast
(Fig. 5E ), and malignant melanoma (Fig. 5F ). This direct
comparison of gelatinolytic activities and proteins specific for
seprase showed that (a) in the assay conditions, in which matrix
metalloproteinases (MMP) were suppressed by EDTA to resolve
serine-type gelatinase activities (Fig. 5C-F), gelatinolytic activities
and proteins specific for seprase were found to be more promi-
nent in tumors than in adjacent normal tissues; (b) 100 to 85 kDa
and 70 to 50 kDa active s-seprase forms recognized by mAb
E97 were abundant in the tumors (Fig. 5C-F). The activated
s-seprase forms are likely dimeric and composed of 65-, 35-, and
25-kDa subunits that were resolved under denaturing conditions
(Fig. 4E).
We detected the presence of s-seprase forms in all of the
malignant tumor tissues examined, including ovarian carcinoma
(Fig. 4), adenocarcinoma of the colon and stomach, invasive ductal
carcinoma of the breast, and malignant melanoma (Fig. 5). After
examining a number of malignant tumor and adjacent normal
tissue samples, we found that, overall, seprase expression and
activation occur more frequently in malignant tumor tissues
(P < 0.0001; Table 1). These data show the prevalence of activated
s-seprase forms in malignant tumors, which corresponds to
increased gelatinase activity (Table 1). Activated seprase in
malignant tumors may be contributing to tumor invasion, in a
way similar to that of the urokinase plasminogen activator (26).
Potential mechanism: proteolytic truncation reduces steric
hindrance for substrates. The construction of seprase is such
that the NH2-terminal end contains a very short cytoplasmic and
transmembrane region that anchors the protease to the surface of
Figure 5. Gelatinase activity and localization of n-seprase in other human tumors. A and B, immunohistochemical localization of n-seprase in human malignant
melanoma. Formalin-fixed, paraffin-embedded human malignant melanoma tissue was sectioned and stained using rat mAb D8 (A ) and the control rat mAb (B). The
slides were then incubated with biotin-conjugated goat anti-rat antibody (Jackson ImmunoResearch, West Grove, PA), stained with strepavidin/alkaline phosphatase
conjugate (Jackson ImmunoResearch), followed by Fast red chromogen in napthol phosphate reconstitution buffer (Biogenex, San Ramon, CA) for the color
development and counterstained with hematoxylin. Note that seprase-positive regions of melanoma cells (open arrow ) and stromal cells (arrow) are stained red.
Bar, 50 Am. C to F, detection of n-seprase-activated forms of different size in invasive carcinomas of the colon (C ), stomach (D ) and breast (E), and in malignant
melanoma (F ). Paired tumor (T ) and adjacent normal (N ) tissues from the same patient were lysed with EDTA-containing lysis buffer. Glycosylated protein captured by
the WGA column from the tissue lysates were analyzed in parallel by gelatin zymography (SG) and immunoblotting (D8 and E97). The protein samples were
loaded under non-boiling, non-reducing conditions to retain gelatinase activity of seprase active forms. The gelatinase activity of serine-type gelatinases (SG) was
detected by incubating the zymogram with 5 mmol/L EDTA to inhibit metalloprotease activity as described (15). Note that two major groups of active s-seprase forms
(100-85 kDa and 70-50 kDa indicated by arrows ) were found by parallel analysis of gelatin zymography and Western immunoblotting. In immunoblotting, mAb D8
recognizes mainly seprase 170-kDa dimeric form and 97-kDa dissociated monomeric form, whereas mAb E97 recognizes all seprase forms, including seprase 170-kDa
dimeric form, 97-kDa monomeric subunit, activated forms of 100 to 85 kDa and 70 to 50 kDa (arrows ), and other inactive shortened forms.
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a cell while allowing for the bulk of seprase, including its putative
catalytic region, to interact with the extracellular milieu. Our
data suggest that reduction of steric hindrance via truncation for
activation can be a useful mechanism to heighten the activity
of seprase. Not only will truncation facilitate access of substrates
to the active site, but it is also a potential means to release soluble
s-seprase. Our model (Fig. 6) reflects the idea that extensive
NH2-terminal truncation reduces steric hindrance and allows for
large substrate molecules to have greater accessibility to the
catalytic site.
Recent structural analysis suggests that it is possible that the
15-Å, triple helical collagen is able to feed through the 24-Å lateral
opening thereby gaining access to the active site (23). Although the
structure meets the diameter requirement, there are other con-
siderations. Classic type I collagen is a 300-nm-long, three-stranded
coil with limited flexibility. All previous studies that examine
n-seprase activity rely on short peptides to assess dipeptidyl
peptidase activity or the denatured form of collagen (gelatin).
A single strand of gelatin is a small fraction of the bulk of the
triple helix, and there is a significant reduction in the rigidity. To
interact with the active site of seprase, gelatin would need to navi-
gate a relatively small opening to be strung through both mono-
mers for seprase to exhibit its characteristic endopeptidase activity.
It is possible that, like interstitial collagenase (27), a Brownian
ratchet-like mechanism feeds the collagen or gelatin through the
lateral opening of both monomers in seprase; however, the initial
process would require an exogenous source of energy, and
this energy requirement is not reflected in the activity of seprase
in vitro . In addition, similar to interstitial collagenase (27), seprase
can liberate from its pro-domain (i.e., NH2-terminal transmem-
brane domain) to interact directly with the collagen that has been
modified by other collagenases (Fig. 6A). In the case of seprase,
Table 1. Detection of active seprase in malignant tumor and adjacent normal tissues
Tumor types Tumor tissue with active seprase
expression/total tumor samples, (%)
Normal tissue with active seprase
expression/total normal samples, (%)
P
Ovarian carcinoma 15/15* (100) 0/6 (0) <0.0001
Breast carcinoma 6/8 (75) 3/8 (37.5)
c
Colon carcinoma 3/4 (75) 1/4 (25)
c
Gastric carcinoma 7/8 (87.5) 2/8 (25) 0.0117
Melanoma 12/13* (92.3) 4/9 (44.4) 0.0132
Total 43/48 (89.6) 10/35 (28.6) <0.0001
NOTE: In tumor and adjacent normal tissue samples, seprase was isolated using WGA column and identified by parallel gelatin zymography and
Western immunoblotting, as shown in Fig. 5C to F .
*Six of 15 ovarian carcinoma samples and 4 of 13 melanoma samples were analyzed by isolating active seprase via immunoprecipitation and subjected
to soluble enzymatic assay for detection of activity, as represented in Fig. 4E to F . Significance of active seprase expression in tumor versus normal
samples, indicated by P, was determined by m2 test.
cAn accurate P could not be calculated due to small sample size; however, these values contribute to the overall significance calculation.
Figure 6. Schematic illustration of a potential seprase
activation process. A, release of membrane-bound
n-seprase. The dimeric form of n-seprase (170 kDa) is
bound to the cell membrane by the NH2-terminal stalk
region and creates a catalytic pocket (orange line ). Likely,
there is more than one overlapping region that contributes
to the dimerization of this protein. The membrane blocks
access to the active pocket when the three-dimensional
structure of the dimer is considered. Activating proteases
cleave the dimer at the stalk region and release it from the
membrane, thereby creating a soluble form like r-seprase
(160 kDa). The separation of the protein from the
membrane reduces steric hindrance and increases
accessibility to the catalytic pocket from below. B, further
NH2-terminal truncation of seprase and increase of
gelatinase activity. Release of NH2-terminal peptides from
the 160-kDa seprase into the 70- to 50-kDa form
extensively reduces steric hindrance and permits even
greater accessibility of substrates to the catalytic site.
The amino acid terminus and domains of seprase are
indicated: C ¶, COOH terminus; N ¶, NH2 terminus;
TM, transmembrane domain, amino acids 7 to 26;
GR, glycosylation-rich region, amino acids 49 to 314;
CR, cysteine-rich domain, amino acids 305 to 466;
CAT, catalytic domain, amino acids 500 to 760.
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perhaps, there is a modification of this mechanism, which involves
increasing the accessibility of the active site by further proteolytic
truncation in a manner similar to the zymogen activation of the
MMPs (Fig. 6B). In this way, seprase activation may facilitate the
invasion of malignant tumor cells through a localized degradation
of components of the extracellular matrix.
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